Long-Term Outcomes with TACE plus RFA for Hepatocellular Cancers

The combination of transcatheter arterial chemoembolization and radiofrequency ablation was associated with a survival benefit compared with RFA alone.

Regional therapies are a key component of treatment of hepatocellular cancers (HCCs) and include transcatheter arterial embolization (TAE) with chemotherapy (TACE) or without and radiofrequency ablation (RFA). Early-stage HCC is treated with hepatic resection and RFA of small lesions.

Investigators report long-term outcomes from an open-label, multicenter, randomized phase 3 trial comparing RFA with or without TACE in patients in China with early-stage HCC amenable to regional therapy without surgery. In the combination therapy arm, TACE was performed first, followed by RFA. Eligible patients had a solitary lesion ≤7 cm in diameter or three or fewer lesions each ≤3 cm in diameter. Of 189 patients randomized, 77% were men, 89% were hepatitis …

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Long-Term Outcomes with TACE plus RFA for Hepatocellular Cancers

Topics

Reviewing Author